Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine

Conditions

Coronary heart disease Circulatory System Coronary heart disease

Alison Offer, Matthew Arnold, Robert Clarke, Derrick Bennett, Louise Bowman et al. (14 authors)

JAMA Network Open2019-03-0119 citations

10.1001/jamanetworkopen.2019.0223

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.

Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Peto R, Collins R.

2010-11-08376 citations

10.1016/s0140-6736(10)60310-8

Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial.

Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage JM, Bowman L, Clarke RJ, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Sleight P, Peto R, Collins R.

2010-06-01218 citations

10.1001/jama.2010.840

SLCO1B1 variants and statin-induced myopathy--a genomewide study.

SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R.

2008-07-231,346 citations

10.1056/nejmoa0801936

Interventions

Simvastatin 80 mg versus 20 mg daily, and separately folic acid 2 mg plus 1 mg vitamin B12 daily or matching placebo tablets.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Men and women who have survivied a heart attack and in whom statin therapy is indicated.

Exclusion criteria

Exclusion criteria: Age under 18 years or over 80 at invitation, contraindications to either study drug, other predominant medical problem.

Design outcomes

Primary

Measure	Time frame
Major vascular events (MVEs) during the scheduled treatment period	—

Secondary

Measure	Time frame
MVEs separately during the first year and in the later years of the study, MVEs in patients subdivided by pre-randomisation lipid levels, MVEs in the presence and absence of the other randomised treatments, major coronary events, total strokes	—

Countries

England, United Kingdom

Outcome results

None listed